Accessibility Menu
Surmodics logo

Surmodics(NASDAQ) SRDX

This security has been delisted. This page is retained for historical reference.

Surmodics last closing stock price
MetricPriceDate
Last closeUSD 42.982025-11-18
Surmodics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.98%USD 40.942025-11-11
1 month+53.55%USD 27.992025-10-17
3 month+16.48%USD 36.902025-08-20
Year to date+8.54%USD 39.602024-12-31
1 year+9.5%USD 39.252024-11-18
3 year+25.45%USD 34.262022-11-18
5 year+14.77%USD 37.452020-11-19
Since inception+957.97%USD 4.061998-03-04

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

SRDX Financials

Key Financial Metrics (TTM)

Gross Margin

71.54%

Operating Margin

-16.05%

Net Income Margin

-18.26%

Return on Equity

-9.50%

Return on Capital

-3.71%

Return on Assets

-6.20%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$88.30M

Operating Income

-$12.35M

EBITDA

-$8.23M

Operating Cash Flow

-$1.88M

Capital Expenditure

-$1.66M

Free Cash Flow

-$3.55M

Cash & ST Invst.

$32.73M

Total Debt

$32.58M

Surmodics Performance Analysis

Surmodics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-09-30USD 105,136,000N/A
20222022-09-30USD 99,951,000-4.9%
20232023-09-30USD 132,584,00032.6%
20242024-09-30USD 126,078,000-4.9%
Surmodics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-09-309.5%
Q12024-12-31-9.9%
Q22025-03-31-6.1%
Q32025-06-305.3%
Surmodics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-09-30USD 0.30N/A
20222022-09-30USD -1.96N/A
20232023-09-30USD -0.11-94.4%
20242024-09-30USD -0.82644.7%
Surmodics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-09-3054.7%
Q12024-12-31-8.3%
Q22025-03-31-38.5%
Q32025-06-30-2.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$29.57M

-2.6%

Gross Profit

$20.99M

-0.2%

Gross Margin

70.99%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

389

N/A

Net Income

-$5.32M

+29.6%

EBITDA

-$5.24M

-86.8%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

$32.73M

-14.3%

Total Debt

$32.58M

-2.6%

Accounts Receivable

$25.02M

+4.0%

Inventory

$15.76M

+2.3%

Long Term Debt

$31.56M

-2.7%

Short Term Debt

$2.05M

+0.3%

Return on Assets

-6.20%

N/A

Return on Invested Capital

-6.15%

N/A

Free Cash Flow

$904.00K

+130.2%

Operating Cash Flow

$1.41M

+169.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KIDSOrthoPediatrics Corp.
$19.82+5.03%
TMCITreace Medical Concepts, Inc.
$4.08+2.00%
CBLLCeriBell, Inc.
$18.13+7.21%
SMLRSemler Scientific, Inc.
$20.33-4.87%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.23+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.